Abstract:Increased expression of BCAT1, the first enzyme catalyzing branched-chain amino acids (BCAA) metabolism, is associated with poor survival in acute myeloid leukemia (AML). Prior studies of BCAT1 or BCAAs in cancer cell metabolism and phenotypes were based on in vitro or ex vivo cultured cells that do not fully recapitulate metabolism in an intact organism; therefore, the in vivo functional and mechanistic roles of BCAA metabolism in normal and malignant hematopoiesis remains unknown. To address this, we established conditional Bcat1 knockout (KO) and knock-in overexpression (OE) mouse models. We found that BCAT1 is dispensable for normal hematopoiesis, whereas BCAT1 OE increases hematopoietic stem cell frequency and function. BCAT1 expression is significantly increased in human primary AML samples containing FLT3 mutations but decreased in AML with MLL abnormalities, raising a fundamental question about how distinct oncogenic drivers create selective metabolic dependencies. Using retroviral and genetic murine leukemia models, we discovered that BCAT1 is required for leukemia initiation and maintenance of FLT3-ITD-driven AML in vivo, and BCAT1 OE synergizes with FLT3-ITD to promote leukemia transformation. In contrast, BCAT1 KO or OE had no effect on MLL-AF9-driven leukemia initiation or maintenance. By integrative analysis of metabolomic, transcriptomic, and metabolic flux profiles of AML-initiating cells with distinct oncogenic drivers, we aim to elucidate the underlying mechanisms responsible for onco-genotype-induced reprogramming of BCAA metabolism. Hence, using stringent genetic studies in preclinical models, our findings not only establish BCAT1 and BCAA as a metabolic dependency of AML-initiating cells in vivo, but also uncover new insights into onco-genotype-induced metabolic rewiring as a selective and targetable vulnerability. Increased expression of BCAT1, the first enzyme catalyzing branched-chain amino acids (BCAA) metabolism, is associated with poor survival in acute myeloid leukemia (AML). Prior studies of BCAT1 or BCAAs in cancer cell metabolism and phenotypes were based on in vitro or ex vivo cultured cells that do not fully recapitulate metabolism in an intact organism; therefore, the in vivo functional and mechanistic roles of BCAA metabolism in normal and malignant hematopoiesis remains unknown. To address this, we established conditional Bcat1 knockout (KO) and knock-in overexpression (OE) mouse models. We found that BCAT1 is dispensable for normal hematopoiesis, whereas BCAT1 OE increases hematopoietic stem cell frequency and function. BCAT1 expression is significantly increased in human primary AML samples containing FLT3 mutations but decreased in AML with MLL abnormalities, raising a fundamental question about how distinct oncogenic drivers create selective metabolic dependencies. Using retroviral and genetic murine leukemia models, we discovered that BCAT1 is required for leukemia initiation and maintenance of FLT3-ITD-driven AML in vivo, and BCAT1 OE synergizes with FLT3-ITD to promote leukemia transformation. In contrast, BCAT1 KO or OE had no effect on MLL-AF9-driven leukemia initiation or maintenance. By integrative analysis of metabolomic, transcriptomic, and metabolic flux profiles of AML-initiating cells with distinct oncogenic drivers, we aim to elucidate the underlying mechanisms responsible for onco-genotype-induced reprogramming of BCAA metabolism. Hence, using stringent genetic studies in preclinical models, our findings not only establish BCAT1 and BCAA as a metabolic dependency of AML-initiating cells in vivo, but also uncover new insights into onco-genotype-induced metabolic rewiring as a selective and targetable vulnerability.

GPRC5C Drives Branched-Chain Amino Acid Metabolism in Leukemogenesis

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

GPRC5A: an Emerging Biomarker in Human Cancer

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

GPR68 Supports AML Cells Through the Calcium/calcineurin Pro-Survival Pathway and Confers Chemoresistance by Mediating Glucose Metabolic Symbiosis

Enhanced Fructose Utilization Mediated by SLC2A5 Is a Unique Metabolic Feature of Acute Myeloid Leukemia with Therapeutic Potential

Therapeutic inhibition of PPAR alpha-HIF1 alpha-PGK1 signaling targets leukemia stem and progenitor cells in acute myeloid leukemia

3160 – METABOLIC REWIRING IN AML-INITIATING CELLS CREATES A SELECTIVE DEPENDENCY ON BCAA METABOLISM

Gossypol acetic acid regulates leukemia stem cells by degrading LRPPRC via inhibiting IL-6/JAK1/STAT3 signaling or resulting mitochondrial dysfunction

Therapeutic Inhibition of PPARα-HIF1α-PGK1 Signaling Targets Leukemia Stem and Progenitor Cells in Acute Myeloid Leukemia

The Lactate Receptor GPR81 is a Mechanism of Leukemia-Associated Macrophage Polarization in the Bone Marrow Microenvironment

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis

Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells.

PRMT1-Mediated Metabolic Reprogramming Promotes Leukemogenesis

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth

PGK1, a Promising Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia Who Are Susceptible to Disease Relapse

BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia